ARTBIO

The ARTBIO Approach: Patients at the Core

Radioligand therapy (RLT) has offered a promising new approach for cancer treatment. While beta radioligand therapies are currently more common in clinical practice, alpha radioligand therapies offer potentially significantly better efficacy and safety to patients. The ARTBIO approach is holistic. It is underpinned by a deep understanding of cancer biology, and the infrastructure needed to effectively design, manufacture, and distribute our therapies. Our patient-centric approach rests on four pillars: Differentiated pipeline, Isotope production: AlphaDirectTM, Ideal isotope: Pb212, ART manufacturing ecosystem. A Differentiated Pipeline is being identified, whereby specific combinations of targets and drug molecules best suited for ART are sought. Our ARTs have high affinity and selectivity in order to effectively kill tumors while sparing healthy tissues. Currently, ARTBIO has four pipeline programs with many more in development; our lead program AB001 has entered first in human studies. Three additional targets (ABA, ABB, and ABC) remain undisclosed. Programs including indications and development stages range from discovery to clinical stage (Phase 1-3) and involve multiple solid tumors.

A team composed of multi-disciplinary experts with decades of experience in advancing complex drugs through all stages of clinical development drives ARTBIO. Founded on a long-standing scientific legacy with nearly a century of pioneering work in radiation therapy, our scientific roots run deep, stemming from research at the University of Oslo and Norway’s Radium Hospital. Our scientific founders, Roy Larsen and Øyvind Bruland, invented Xofigo, the first metabolically targeted alpha therapy. We pride ourselves on combining creativity and scientific expertise, valuing inclusion, collaboration, and fostering strong relationships with our team and partners in health care.